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of their changes in comparison with previous years is very important 
for effective pharmacovigilance (PV) (eg, taking of regulatory acts, 
update of instructions for use, revealing of medical mistakes).
Patients (or Materials) and Methods: To analyze structure of ADR, 
we used search in ARCADe (Adverse Reactions in Crimea Autonomy 
DatabasE).
Results: In 2012, Regional PV office of State Expert Center of 
Ukraine in Simferopol (Crimea Autonomic Republic) received 1135 
spontaneous reports about ADR from 123 hospitals. As in 2006-
2011 period, most frequently ADR were registered in 1-st year 
children (98 cases) and 46 to 60 year-old adults (259). Sixty-five 
percent of reports informed about ADR in females, 35% in males. 
Two reactions were lethal (both in children, uncertain causality), 72 
were life-threating, 102 resulted in hospitalization of patient, and 
181 in temporary disability. Most of drugs were used per os (575), 
others were prescribed intramuscularly (190), intravenously (239), 
or in topical forms (69 reports). A total of 133 patients had allergy 
in anamnesis, 73 from them had medicinal allergy. A total of 328 
patients took only 1 product (monotherapy), when other took com-
binations of drugs, from them 113 patients 5 medicines and more. 
Most frequently drugs were prescribed for treatment of respiratory 
diseases (269), heart diseases (176), and infections (148). A total of 
563 reports informed about skin rush, 115 about dyspeptic disorders, 
96 about central neural system symptoms, 53 about fever, 53 about 
hemopoiesis depression, 37 and 15 about angioneurotic edema and 
anaphylactic shock, respectively. In 71%, ADRs needed medical cor-
rection–prescription of additional drugs. The structure of ADR data 
according to groups is following: 41% of reactions were caused by 
systemic antimicrobial agents (ATC J01-J07), 12% by cardiovascular 
drugs (C01-C10), 8.3% by drugs influencing on CNS, and 7.5% by 
nonsteroidal anti-inflammatory drugs. The top 3 of products use of 
which resulted in ADR includes: ceftriaxone (62 cases), zidovudine/
lamivudine combination (52 cases), and ceftazidime (37 cases).
The most frequent errors found during analysis were ignoring of 
allergic anamnesis, off-label use (ignoring of age limits, pregnancy, 
lactation, contraindications), overdosage, and breaches of treatment 
regimen.
Conclusion: Regular analysis of ADR data received from doctors 
allows to define specific patterns of reactions development, phar-
macologic groups of high risk of complications and most frequent 
medical errors. Knowledge of them let clinical pharmacologists, regu-
latory agency, and educational societies to focus on the issues really 
important for effective and safe pharmacotherapy.
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Introduction: Drug-associated acute liver injury is a common con-
cern in drug safety, especially acute liver failure leading to registration 
for transplantation (ALFT). SALT was designed to explore drug-
associated ALFT.
Patients (or Materials) and Methods: French ALFT cases exposed 
to drugs within 30 days of first symptoms were compared with 
drug utilization data from the 1/97 sample of the French National 
Healthcare database (EGB). Event rates were computed per billion 
DDD dispensed over the period and per million users, compared 
with the average number of DDD dispensed per user over 3 years. 
Chronic liver disease, documented clinical causes, and drug overdoses 
were excluded.
Results: The 65 cases of ALFT identified in France (2005-2007) had 
been exposed to 235 different drugs. The drug classes most found 
were paracetamol (47 cases), anxiolytics (n = 13), antiepileptic drugs 
(n = 11), NSAIDs (n = 10), H1 antihistamines (n = 8), proton pump 
inhibitors (n = 7), and antidepressants (n = 6). Other classes were 
associated with ≤5 cases. Rates ranged from 1.9 (bromazepam) to 
372 cases per billion DDD (prazepam). Per user rates ranged from 
0.19 (pantoprazole) to 56 per million (phenytoin). For NSAIDs, PPI, 
and some H1 antagonists, event rates decreased with increasing aver-
age number of DDD dispensed. In these classes, the event rate per 
user was below 1 per million users. For other drug classes such as 
antiepileptic drugs, the event rates per billion DDD were similar, and 
rates per million users increased with increasing average number of 
DDD dispensed per subject. Drugs fell into 3 main categories: event 
rates below 1 per million users (NSAIDs, PPI, most antihistamines, 
some benzodiazepines), from 1 to 10 per million users (paracetamol, 
benzodiazepines, antiepileptic drugs), and above 10 per million users. 
Antidepressants were ~1 case per million users. Two antiepileptic 
drugs had event rates at or above 10 per million users. Overall, drugs 
with longer duration of use tended to have higher per user event rates.
Conclusion: These results are still tentative because of the small num-
ber of cases for individual drugs. SALT should be extended.
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Introduction: In South Africa, mental health services are underre-
sourced, and management of psychiatric disorders is poorly inte-
grated into the primary health care system. Despite the statistic that 
neuropsychiatric disorders are ranked third in the national burden 
of disease (following HIV/AIDS and the category “other infectious 
diseases”), little has been done to document the current services to 
improve mental healthcare systems. The aim of this research, there-
fore, was to establish a baseline of antidepressant utilization in vari-
ous sectors of health service offered in Gauteng, South Africa’s most 
populous province. This particular segment reports on antidepressant 
usage in a sample of dispensing doctors prescriptions in 2 geographic 
locations in Gauteng.
Patients (or Materials) and Methods: Two datasets (A and B) 
were acquired from different medical data warehousing compa-
nies. Each dataset comprised 1 years’ medical records from health 
care practitioners subscribed to the respective company (Dataset A 
from 2009, Dataset B from 2011). Data included a unique patient 
number, age, gender, treatment code, ICD-10 code, and treatment 
date. Microsoft Excel was used to filter the data and isolate patients 
treated with an antidepressant and a cluster analysis performed to 
group antidepressants together. Simple descriptive statistics were 
determined. Data were analyzed using STATA (v10.0). Statistical 
significance was determined using Pearson’s chi-squared tests, Mann 
Whitney U test, and logistic regression. Significance levels were set 
at P < 0.05.
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Results: For dataset A, n = 9213 and B, n = 1244. The most fre-
quently dispensed antidepressant was amitriptyline (A: 67.75%, 
n = 6242; B: 64.06%, n = 797). The mean age of patients was 43.86 
(13.81) and 46.27 (13.07), respectively. The type of antidepressant 
used was significantly associated with ICD-10 code, psychiatric 
condition, and categorical age (P < 0.0001). The mean number of 
antidepressant prescriptions per patient were: A, 2.95 (3.77); and B, 
2.57 (2.47). Duration of treatment was related to age, ICD-10 code, 
and psychiatric condition (P < 0.0001).
Conclusion: Since their inception, there has been a steady increase 
in global antidepressant prescriptions, despite controversies concern-
ing efficacy and safety of these drugs. This trend is also evident in 
South Africa: This research shows that amitriptyline accounts for a 
majority of prescriptions because of its varied indications for use. 
The determinants of the type of antidepressant used showed that 
patients with a psychiatric condition were more likely to receive a 
newer antidepressant, and patients with a pain condition were more 
likely to receive an older antidepressant. These results will ultimately 
be compared with DUR data from the private and general public 
sectors of Gauteng health services to establish a baseline for making 
recommendations concerning safety, efficacy, and cost-effectiveness 
of antidepressant use in Gauteng.
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Introduction: Pregabalin, an agent in treating partial epilepsy and 
peripheral neuropathic and central pain, was studied for its effect on 
driving performance in healthy volunteers. The study was approved 
by the ethical committee of Ehime University Hospital. Written 
informed consent was obtained from the volunteers before partici-
pation in the study, which was performed in accordance with the 
principles of the Declaration of Helsinki.
Patients (or Materials) and Methods: Sixteen regularly driving, 
healthy male volunteers were enrolled for a double-blind placebo 
control study of pregablin on driving performance. Driving simulator 
was used to test the simple and complicated braking reaction time, 
simple and complicated steering wheel techniques. Pregabalin was 
also evaluated for the effect of training on driving tests.
Results: The mean (SD) age of pregabalin and placebo groups were 
26.0 (2.9) and 28.6 (3.5) years, respectively. The body weight, plasma 
creatinine level, and eGFR of pregabalin group were 69.0 (4.7) kg, 
0.8 (0.04) mg/dL, and 94.1 (5.7) mL/min, respectively. The body 
weight, plasma creatinine level, and eGFR of placebo group were 
62.16 (4.6) kg, 0.8 (0.05) mg/dL, and 96.7 (6.5) mL/min, respectively. 
Six members of the pregabalin group and 2 members of placebo 
group reported sleepiness. The other 2 members of the pregabalin 
group presented somnolence during driving. All the subjects showed 
no serious adverse effects. There were no significant differences of 
both simple and complicated braking reaction time between pregaba-
lin and placebo groups. The simple and complicated wheel techniques 
also showed no differences between pregabalin and placebo groups. 
In comparing the effect of training on the driving performance, the 
placebo group showed the improvement in the test of simple steering 
wheel technique. The number of errors in handling wheel detected 1 
hour and 2 hours from the baseline showed significantly reduction 
compared with the baseline data. However, the pregabalin group 
showed no improvement in handling wheels with the training. Both 
pregabalin and placebo groups had no changes in both simple and 
complicated braking reaction time, and complicated handling wheel 
tests.
Conclusion: In our study using driving simulator, pregablin exhibited 
no serious central nervous system side effects in engaging driving, but 
caused mild effects to decrease the training of driving.
Disclosure of Interest: M. Nomoto: Nothing to declare. T. Tsujii: 
Nothing to declare. W. Kyaw: Nothing to declare. N. Nishikawa: 
Nothing to declare. H. Iwaki: Nothing to declare. M. Nagai: Nothing 
to declare.
PP036—HEPATOTOXICITY IN ACUTE AND 
REPEATED SUPRATHERAPEUTIC PARACETAMOL 
INGESTION IN CHILDREN AND ADOLESCENTS. 
RETROSPECTIVE COHORT STUDY CONDUCTED 
BETWEEN 2005 AND 2010
H.Y. Tong*; C. Zegarra; N. Medrano; A. Borobia; A. Carcas;  
J. Frías; and E. Ramirez
Clinical Pharmacology Service, La Paz University Hospital, 
Madrid, Spain
Introduction: To calculate the incidence, describe the suspected cases 
of paracetamol poisoning, and determine the differences between the 
patterns of acute versus chronic ingestion in patients < 18 years of 
age who were treated at a tertiary hospital.
Patients (or Materials) and Methods: Retrospective cohort study 
of patients < 18 years of age who were treated in the emergency 
department (pediatric and general) of the La Paz University Hospital 
for suspected paracetamol intoxication and for whom paracetamol 
serum level tests were requested.
Results: Ninety-two (92) patients with suspected paracetamol 
poisoning were identified between 2005 and 2010. The incidence 
for 2007 was 1.53 cases (95% CI Poisson, 0.24–5.57) per 10,000 
patients treated at the pediatric emergency department. The most 
common cause of poisoning was attempted suicide (47.8%), with a 
median age of 15 years, followed by accidental poisoning (42.2%), 
with a median age of 2.65 years. Following the assessment of causal-
ity, we found that 1 patient with acute poisoning showed a hepatic 
disorder secondary to paracetamol, while 7 of the 11 patients with 
chronic poisoning showed liver enzyme disorders secondary to par-
acetamol poisoning. The time required to find medical care was 6.83 
hours for acute poisoning and 52.3 hours for chronic poisoning 
(P < 0.001).
Conclusion: Chronic paracetamol poisoning is a potential risk factor 
for hepatotoxicity and ALF; delays in seeking medical help may be a 
contributing factor. The parents/guardians should therefore be noti-
fied of this fact, and the ED physicians’ clinical suspicion increased.
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Introduction: Misuses of buprenorphine concern ~30% of patients 
treated for drug detoxification in cases of opioid abuse. Injecting pills 
that are not intended for intravenous (IV) administration may have 
harmful consequences, particularly because of particles. The main 
difference between Subutex® and its generics concern the insoluble 
